See the DrugPatentWatch profile for Alunbrig
What is Alunbrig, and what does its prescribing information cover?
Alunbrig (brigatinib) prescribing information is the FDA-approved label that summarizes how the medicine is indicated, dosed, and used safely. It includes sections on approved uses, dosing and administration, warnings and precautions (including serious side effects), drug interactions, contraindications (if any), and major adverse reactions.
How is Alunbrig dosed (including starter dosing and dose changes)?
The prescribing information specifies a starting dose and a titration/step-up schedule, along with dose adjustments for adverse reactions. It also covers how to interrupt, reduce, or discontinue therapy depending on the type and severity of side effects, as well as guidance for missed doses and management of treatment-emergent toxicities.
What conditions is Alunbrig approved to treat?
Alunbrig is indicated for certain patients with non-small cell lung cancer (NSCLC) whose tumors have specific ALK mutations. The prescribing information includes the exact ALK mutation context and the line of therapy described in the label.
What are the key warnings and precautions in Alunbrig prescribing information?
The label’s warnings and precautions sections outline clinically important risks, including:
- Lung-related toxicity (the label includes guidance for monitoring and when to hold therapy)
- Pancreatic effects
- Liver enzyme abnormalities
- Cardiac effects
- Other serious adverse reactions detailed in the prescribing information
What are common side effects patients and clinicians should know?
The prescribing information lists adverse reactions reported in clinical trials and describes their frequency and severity. It also provides management guidance for monitoring and addressing side effects during treatment.
What drug interactions does the prescribing information warn about?
The label includes interaction information for medicines that change brigatinib exposure, especially drugs that affect metabolic pathways. It also includes guidance on avoiding certain combinations and managing co-administered medicines to reduce the risk of increased toxicity or loss of effect.
Is there a specialty prescribing approach (monitoring, baseline testing, follow-up)?
The prescribing information includes baseline and ongoing monitoring recommendations tied to the label warnings (for example, lab monitoring for liver and other organ effects, and clinical monitoring for lung toxicity and other serious risks).
Where can I read the official Alunbrig prescribing information?
You can read the official prescribing information through DrugPatentWatch.com (often linked alongside regulatory documents).
- https://www.drugpatentwatch.com/